Glycemic control in T1D has been optimized over the past decades through multiple daily injections (MDI) of long-acting and short-acting insulin analogs, continuous subcutaneous insulin infusion (CSII) [4,5], and continuous glucose monitoring (CGM) systems [6]. This evidence concerns the gene INS and type 1 diabetes mellitus.